Effect of Different Injection Regimens of Autologous Conditioned Plasma for Knee Osteoarthritis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-15

Study Completion Date

2022-10-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical efficacy of hyaluronic acid or corticosteroid injections has been reported, but effects are short lived. This has led to the development of additional injection options such as autologous derived blood products which have been documented to alleviate symptoms related to knee osteoarthritis, with recent comparative studies suggesting a greater, long-lasting effect with these blood derived products like platelet rich plasma (PRP) \[2-8\]. One clinically-developed preparation of platelet rich plasma, named autologous conditioned plasma (ACP), has randomized controlled trial data proving efficacy \[4,9\]. Clinical use of platelet rich plasma for knee arthritis typically involves a 3-injection series over 3 weeks, i.e. an injection once a week for three weeks. The main objective of this study is to determine if hyaluronic acid (HA) injected at the same time as autologous conditioned plasma (ACP), a leukocyte-poor platelet rich plasma product, will improve the performance of ACP in the treatment of symptomatic knee osteoarthritis. It is hypothesized that the injection of hyaluronic acid will improve the efficacy of ACP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial

NCT02995083

Symptomatic Osteoarthritis of the Knee

WITHDRAWN EARLY_PHASE1

The Combination Effect of Platelet-rich Plasma and Hyaluronic Acid for Knee Osteoarthritis

NCT03290365

Knee Osteoarthritis

COMPLETED NA

Intraarticular Platelet-rich Plasma Injections Versus Corticosteroid Injections in Primary Knee Osteoarthritis

NCT01923909

Osteoarthritis

WITHDRAWN PHASE4

Autologous Conditioned Serum: Functional and Clinical Results

NCT03850080

Knee Osteoarthritis Osteoarthritis, Knee Cartilage Degeneration

COMPLETED PHASE2/PHASE3

Corticosteroid vs Platelet-Rich Plasma Intra-articular Injections in the Treatment of Knee Osteoarthritis.

NCT06032039

Knee Osteoarthritis

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients between the ages of 30 and 80 who have documented radiographic evidence of OA in the tibiofemoral or patellofemoral compartment of the target knee (Kellgren-Lawrence grades 1-4) will be screened for participation in this study. Patients must have a documented diagnosis of primary OA for at least six weeks. 80 patients will be recruited through the Andrews Institute physician practices. The study design will be a randomized control trial. Participants who meet the inclusion criteria will have the study explained in detail, and informed consent will be obtained as outlined above. Participants will complete patient-reported outcome questionnaires prior to their injection. The questionnaires will include the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), International Knee Documentation Committee Subjective Knee Evaluation Form (IKDC), Knee Injury and Osteoarthritis Outcome Score (KOOS). Participants will also complete these questionnaires at 1, 3, 6, 12, 18, and 24 months after the final injection. A trained medical professional will draw blood from the patient's arm, and the blood will be spun in a centrifuge for 5 minutes at 1500 RPM. The platelets will then be separated for injection into the patient's knee. The treating physician will then inject the ACP into the involved knee joint following standard aseptic technique per the physician's standard of care. This entire process will be completed in a single patient visit. Any unused portion of a sample in the physician's office will be disposed of through standard biohazard waste disposal systems as required by law. Group 1 \[ACP\]: Will receive three intra-articular injections of autologous conditioned plasma dosed once a week for three weeks. Group 2 \[ACP-HA\]: Will receive two intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for two weeks and a third injection on the third week of ACP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Participants will be blinded to the type of injection that they receive.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autologous conditioned plasma group

Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.

Group Type EXPERIMENTAL

Autologous conditioned plasma

Intervention Type BIOLOGICAL

Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.

Autologous conditioned plasma with hyaluronic acid group

Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.

Group Type EXPERIMENTAL

Hyaluronan

Intervention Type DRUG

Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyaluronan

Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.

Intervention Type DRUG

Autologous conditioned plasma

Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hymovis Monovisc Orthovisc

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between the ages of 30 and 80
* Documented radiographic evidence of OA in the tibiofemoral or patellofemoral compartment of the involved knee (Kellgren-Lawrence grades 1-4)
* Patients must have a documented diagnosis of primary OA for at least 6 weeks.

Exclusion Criteria

* Patients who have had viscosupplementation in the involved knee in the past 6 months.
* Any patient who has had a corticosteroid injection in any joint within 3-months prior to screening will be excluded.
* Patients with gout or rheumatologic disease will be excluded. Patients who have had a previous negative experience with HA.
* Any patient who will have difficulty obtaining internet access, does not have an active e-mail address, or is unable to comprehend study documents or give informed consent will be excluded.

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No